1393 related articles for article (PubMed ID: 19243060)
1. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
2. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
3. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
5. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
[TBL] [Abstract][Full Text] [Related]
6. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver.
Tamada T; Ito K; Yoshida K; Kanki A; Higaki A; Tanimoto D; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e284-8. PubMed ID: 21296514
[TBL] [Abstract][Full Text] [Related]
8. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
9. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.
Tsuda N; Okada M; Murakami T
Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
11. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
12. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
13. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Kitamura T; Araki T
J Magn Reson Imaging; 2009 Nov; 30(5):1042-6. PubMed ID: 19856436
[TBL] [Abstract][Full Text] [Related]
14. Whole-body MRI with assessment of hepatic and extraabdominal enhancement after administration of gadoxetic acid for staging of rectal carcinoma.
Huppertz A; Franiel T; Wagner M; Püttcher O; Wagner J; Rief M; Schwenke C; Hamm B; Strassburg J
Acta Radiol; 2010 Oct; 51(8):842-50. PubMed ID: 20698804
[TBL] [Abstract][Full Text] [Related]
15. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
Zizka J; Klzo L; Ferda J; Mrklovský M; Bukac J
Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
[TBL] [Abstract][Full Text] [Related]
16. Fat-suppressed dynamic and delayed gadolinium-enhanced volumetric interpolated breath-hold magnetic resonance imaging of cholangiocarcinoma.
Leyendecker JR; Gakhal M; Elsayes KM; McDermott R; Narra VR; Brown JJ
J Comput Assist Tomogr; 2008; 32(2):178-84. PubMed ID: 18379298
[TBL] [Abstract][Full Text] [Related]
17. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.
Tamada T; Ito K; Sone T; Kanki A; Sato T; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e207-11. PubMed ID: 20869827
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
19. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate.
Schmid-Tannwald C; Herrmann K; Oto A; Panteleon A; Reiser M; Zech C
Acta Radiol; 2012 Nov; 53(9):961-5. PubMed ID: 23024179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
